Pay in 4 interest-free payments of $5.40 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
The decision to use GLP-1 receptor agonists should be made on an individual basis, weighing the potential benefits against the risks for each patient
Mo1908: Glucagon-like peptide-1 receptor agonist use in patients with perianal fistulizing Crohn's disease is well tolerated and leads to weight loss and clinical improvement in fistula activity
Food and Drug Administration recently issued a warning against using unapproved GLP-1 drugs for weight loss, citing quality concerns, false or misleading labels, counterfeit drugs and more than 1,600 reports of adverse effects associated with compounded GLP-1 medications
The jump from 8 mg to 12 mg, where glucagon receptor engagement becomes more complete, produced measurable additional weight loss in the clinical data
This drug has been shown to reduce weight by 21% in people with obesity, which is equivalent to a person weighing 100 kg losing about 21 kg
In addition, reliance on diagnostic coding may underestimate the true incidence of suicidal ideation, as sensitivity and specificity of such codes are uncertain
